Mohammed Majam

Datos Biográficos

ID7796136
NOMBREMohammed Majam
NOMBRESMohammed
APELLIDOMajam
FIRMAMAJAM M
AFILIACIONESUniversity of the Witwatersrand
ORCID0000-0003-0302-5353
VERIFICADOSí
TOTAL DE OBRAS6
TOTAL DE CITAS0
TOTAL COMO AUTOR6
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2017
AÑO MÁS RECIENTE DE PUBLICACIÓN2023
ÍNDICE H0

  • Acceptability, feasibility, and accuracy of blood-based HIV self-testing

    Open AccessBao Vu Ngoc, Mohammed Majam et al.ARTICLEPLOS Global Public Health2023

    HIV self-testing (HIVST) is an effective approach to increase testing uptake. While oral fluid-based HIVST has been rapidly scaled, use of blood-based HIVST remains limited. We evaluated the acceptability, feasibility, and accuracy of blood-based HIVST among lay users in Ho Chi Minh City (HCMC), Vietnam. We conducted a cross-sectional study among HIV testing clients at the HCMC Pasteur Institute from March 2019 to October 2020. Participants recei…

  • Planning and commitment prompts to encourage reporting of HIV self-test results

    Open AccessAlison M Buttenheim, Laura Schmucker et al.ARTICLEPLOS Global Public Health2022

    Reporting of HIV self-test results to encourage linkage to HIV care for those who receive a positive test result is a common challenge faced by HIV self-testing programs. The impact of self-testing programs is diminished if individuals who obtain a self-test do not use the test or seek confirmatory testing and initiate HIV treatment following a positive result. We conducted a cluster randomized trial of two interventions designed to increase repo…

  • The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa

    Open AccessKatleho Matsimela, Linda Sande et al.ARTICLEBMJ Global Health2021

    BACKGROUND: Countries around the world seek innovative ways of closing their remaining gaps towards the target of 95% of people living with HIV (PLHIV) knowing their status by 2030. Offering kits allowing HIV self-testing (HIVST) in private might help close these gaps. METHODS: We analysed the cost, use and linkage to onward care of 11 HIVST kit distribution models alongside the Self-Testing AfRica Initiative's distribution of 2.2 million HIVST k…

  • The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa

    Open AccessLise Jamieson, Leigh F Johnson et al.ARTICLEBMJ Global Health2021

    BACKGROUND: HIV self-testing (HIVST) has been shown to be acceptable, feasible and effective in increasing HIV testing uptake. Novel testing strategies are critical to achieving the UNAIDS target of 95% HIV-positive diagnosis by 2025 in South Africa and globally. METHODS: We modelled the impact of six HIVST kit distribution modalities (community fixed-point, taxi ranks, workplace, partners of primary healthcare (PHC) antiretroviral therapy (ART) …

  • Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe

    Open AccessLinda Sande, Linda Alinafe Sande et al.ARTICLEBMJ Global Health2021

    INTRODUCTION: As countries approach the UNAIDS 95-95-95 targets, there is a need for innovative and cost-saving HIV testing approaches that can increase testing coverage in hard-to-reach populations. The HIV Self-Testing Africa-Initiative distributed HIV self-test (HIVST) kits using unincentivised HIV testing counsellors across 31 public facilities in Malawi, South Africa, Zambia and Zimbabwe. HIVST was distributed either through secondary (partn…

  • Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial

    Open AccessFrançois Venter, Willem D F Venter et al.ARTICLEBMC Public Health2017

    Hepatitis B continues to be a common co-infection in HIV-infected adults, and adds complexity to management of ART switches involving tenofovir. Routine renal and haematological screening prior to ART detected few abnormalities. The use of these screening tests should be assessed among patients with higher CD4 counts, who may even have fewer abnormalities. Formal evaluation of cost-effectiveness of laboratory screening prior to ART is warranted